Рет қаралды 157,419
Pfizer / BioNTech
m RNA
N = 43,538 participants
94 people infected so far
90% effective
Antibodies and T cells
Mostly mild to moderate side effects
RNA falls apart
Minus 80 degrees Celsius (minus 112 degrees Fahrenheit)
Dry Ice, -78 degrees Celsius
AstraZeneca / University of Oxford
Chimpanzee adenovirus
US, 1.2 billion for 300 million doses
EU, 400 million doses
Indian studies and production
India’s Serum Institute
2 billion doses next year
Results from trial by end of December
Moderna / National Institutes of Health
mRNA, to produce viral proteins in the body
Providing nearly $1 billion in support
October, finished recruiting 30,000
Including 7,000 people 65 years +
Emergency use authorization by the end of 2020
US, 100 million doses
Canada, Japan, Qatar
Johnson & Johnson
Adenovirus based
Ebola technology
US funding, 456 million
US, One billion for 100 million doses
EU, 200 million doses
Phase 3 launched in September, 60,000
Single dose vaccine
Results in December
Brazil
Halted phase 3 trial of a Chinese vaccine
Serious adverse incident reaction in a participant, 29th October
CoronaVac (Sinovac)
One of 11 vaccines currently at stage 3 trials
Patient confidentiality
Officials in China allowed emergency use
Tens of thousands of doses already given
Russia
Sputnik V
Two human adenoviruses (common cold)
92 per cent effective
Interim results, 16,000 trial participants
Two-dose vaccine, 3 weeks apart
Domestic Rollout
Phase three study, Gamaleya Institute
29 clinics across Moscow
40,000 volunteers in total
A quarter receiving a placebo shot.
Turkey to start production